GlaxoSmithKline 3Q Revenues: $11.1 billion (+5% in USD, -3% in local currency) 3Q Earnings: $2.7 billion (+2% in USD, -6% in local currency) YTD Revenues: $33.3 billion (+6% in USD, -3% in local currency) YTD Earnings: $8.4 billion (+8% in USD, -1% local currency) Comments: The weak dollar bolstered the appearance of GSK’s results, but the numbers in GBP show a down quarter. Avandia’s safety concerns walloped GSK’s pharma growth in 3Q, with sales dropping 51% to ...